Steven Holtzman

Steven Holtzman General Information

Biography

Mr. Steven Holtzman is a Co-Founder and serves as Board Member at Shoreline Biosciences. Mr. Holtzman serves as Chief Executive Officer, President and Board Member at Decibel Therapeutics. Mr. Holtzman served as Board Member at Warp Drive Bio. He also serves as Chairman at QIhan Biotech. He serves as Executive Chairman and Board Member at Manifold Bio. He is a Board Member at Sync Project. He is an Advisor of Humatics. He served as an Executive Vice President, Corporate Development at Biogen. Previously, he is the Founder and served as Chairman of Infinity Pharmaceuticals. Steven Holtzman joined Decibel as president and chief executive officer in 2016. Steve brings more than 30 years of strategic, operational and leadership experience in the biotechnology industry. Prior to Decibel, he served as executive vice president, corporate development at Biogen, Inc., where he created and led the program leadership and management group through six new drug approvals. He also led the business development and M&A group through successful completion of numerous transactions. Prior to Biogen, Steve served as the founder, chief executive officer and chair of the board of directors of Infinity Pharmaceuticals, Inc., a cancer drug discovery and development company. He was also an early leader and the chief business officer of Millennium Pharmaceuticals (now Takeda Oncology), a pioneer in large scale genetics and genomics, and was a founder, member of the board and the executive vice president of DNX Corporation, the first transgenic animal company. From 1996 to 2001, he served as a Presidential appointee to the U.S. National Bioethics Advisory Commission. Steve received his B.A. in philosophy from Michigan State University and his B.Phil. graduate degree in philosophy from Corpus Christi College, Oxford University, which he attended as a Rhodes Scholar. He also served as Advisor at PureTech Health.